After a drug is withdrawn, who bears patients’ losses?

Before the Conclusion | Final article in the series “After Approval: Drugs Reconsidered”

When a drug leaves the market, medicine or regulation has changed its judgment. For people who have already taken it, however, the story rarely ends with an announcement. How will their treatment continue? What happens to the money already spent? Is an injury related to the drug, and will anyone take responsibility for the consequences?

Some of the preceding five stories have outcomes extending many years later; others remain amid disputes over withdrawal of approval. Together they remind us that deciding whether a drug should be used in the future and addressing losses already incurred require different work.

Vioxx reached a personal-injury settlement for which actual payments were subsequently recorded. The proposed $69 million avacopan settlement currently attracting attention, by contrast, concerns investors’ securities claims. These sums may appear in similar news stories about drug controversies, but they cannot be treated as the same kind of compensation for patients.

A withdrawal decision first changes the future

When regulators reassess a drug’s benefits and risks, their main question is whether, on the available evidence, patients should still begin or continue this exposure. Actions may include adding warnings, restricting the eligible population, withdrawing a use, or ending commercial supply.

Past losses take different forms. Some people have suffered drug-related injuries. Others have paid treatment costs or spent time they cannot recover. All deserve serious attention. Whether a particular legal process can provide relief, however, depends on the facts, the grounds for liability, and the procedural rules.

A new study that fails to confirm efficacy therefore does not automatically establish whether each patient suffered a compensable injury. Nor does a regulatory finding automatically complete an individual assessment for everyone. Removing a risk from future use and establishing what caused a past injury are related but distinct tasks.

Vioxx: how a personal-injury settlement moved toward payment

Vioxx left the market in 2004. In 2007, Merck and the relevant plaintiffs’ lawyers agreed to a U.S. settlement program totaling $4.85 billion to address eligible claims involving myocardial infarction, ischemic stroke, and related injuries. The company’s original announcement explicitly stated that this was not a patient class-action settlement into which everyone who had used the drug was automatically enrolled. Claims required individual assessment. [1]

The total first describes the size of a program. Eligibility, evidence requirements, and allocation of funds still have to be addressed. We cannot divide the fund by everyone who ever took the drug and announce how much each patient should receive.

The program also progressed beyond the announcement of a sum. Merck’s second-quarter 2010 report recorded that the relevant myocardial infarction and stroke claims had been resolved and final payments made. This allows us to say that there is a record of actual compensation, rather than only a promise awaiting implementation. [2]

Actual payments still do not mean that every loss suffered by every user was made good. The program specified eligible claim types, participation requirements, and a geographic scope. Injury eligibility, legal fees, allocation rules, and money actually received are matters that need separate examination.

Two other sets of figures also need attention. Merck later reached an $830 million securities settlement addressing investor claims. Another resolution, totaling $950 million and announced by the U.S. Department of Justice in 2011, concerned matters including unlawful promotion and comprised a criminal fine and civil settlement. These amounts cannot be added to the $4.85 billion and collectively called “money paid to patients.” [3,4]

The same drug can involve patients, investors, and government simultaneously. To identify what a payment resolves, first establish who receives it and which legal matter it concerns.

Avacopan: settling a shareholder case does not settle patients’ questions

The avacopan securities case concerns investors who purchased ChemoCentryx shares during a specified period. The proposed $69 million settlement addresses claims associated with those stock transactions. The agreement also explicitly states that the settlement is not an admission of wrongdoing by the defendants. As of this article’s verification date, the settlement-approval hearing was scheduled for October 29, 2026. It cannot be described as compensation already paid in full. [5]

That hearing primarily reviews the settlement, allocation, and related matters. It cannot determine whether the drug may remain on the market. The U.S. FDA’s withdrawal-of-approval process runs separately, as does a journal’s process for deciding whether to retract a paper. None substitutes for the others. [5,6]

The claims released by the agreement relate to specified stock transactions. This cannot be interpreted directly as resolving patients’ drug-injury claims. A private securities settlement also cannot establish that the government has completed every investigation into responsibility.

There have already been calls to address accountability to patients. Vasculitis International has publicly emphasized the need for clear accountability for breaches of data integrity while taking patients’ need for access to treatment seriously. U.S. law firms are also investigating and soliciting cases involving severe liver injury and families of patients who died. [7]

Patient-organization statements, law firms seeking cases, formal lawsuits, settlements or judgments, and actual payments nevertheless represent different stages. A case-solicitation advertisement alone cannot establish that patients have received compensation. Equally, failure to locate payment outcomes does not establish that every avenue for patients is closed.

Avacopan therefore leaves a question that requires continued attention: even if the investor case ultimately ends, someone must still verify whether patient-related injuries have been established and whether effective avenues for relief have been pursued.

What do free supply, reimbursement, and refunds each address?

When Relyvrio was withdrawn, existing patients could move to a free-drug program after discussing it with their physicians. The company’s 2024 annual report stated that the final supply covered the period through early 2025. This addressed continuity of treatment during withdrawal. It was neither compensation for earlier injuries nor repayment of all patients’ prior drug costs. [8]

Product returns, rebates, and sales adjustments in company financial statements also require attention to the parties involved. They may concern distribution channels, payers, and contractual settlements. The appearance of refunds or expense reductions in a report does not establish that all patients have received compensation. [8]

Further checking also identified Amylyx’s disclosure of a separate $6.5 million investor-settlement arrangement concerning statements about Relyvrio’s commercial results and prospects. Both the company’s SEC filing and the announcement by the law firm representing the plaintiffs identify securities-transaction claims as the subject. This, too, is not a patient-injury fund and cannot establish that patient compensation is complete. Nor can litigation about commercial statements be reported directly as a judicial finding of clinical-trial fraud. [12]

When Mylotarg left commercial supply in 2010, Pfizer’s announcement allowed patients already taking it, or who had already received a prescription, to discuss completing treatment with their physicians. New patients would require their physician to submit an IND. These arrangements addressed continued access to treatment, a different question from whether costs should be refunded or past injuries compensated. [9]

Bevacizumab presents another situation. After its breast-cancer indication was withdrawn in the United States, the drug remained available for other cancer uses. The FDA separately explains off-label use of approved medicines. Whether a prescription can be written and whether a payer will cover it are not exactly the same decision. Researchers studying historical claims data found that understanding use and payment after the regulatory decision required considering both physicians’ decisions and coverage policies. [10,11]

All these arrangements can affect patients, but they address different difficulties. Continued access does not mean the treatment’s benefits have been re-established. Financial assistance also cannot automatically be equated with accepting responsibility for drug-related injury.

Five cases with different kinds of follow-up

Putting the verified material together reveals several different stages of progress.

“Did not locate in this review” must retain its qualification. Private individual cases, proceedings in other countries, and unpublished settlements may fall outside the search. We should not fill gaps in the public record with speculation.

There is still a distance between announcing a sum and obtaining relief

The Vioxx follow-up is useful because it shows that a relief program needs practical points of entry. Who may apply? How are medication and medical records submitted? How is eligibility reviewed? How are disputes reconsidered? When are funds distributed?

At the same time, a drug’s risks, an illness occurring after someone takes it, and the drug having caused that person’s particular injury cannot simply be equated. The relevant process must also examine causation and the basis for responsibility. Requirements differ across legal contexts. One settlement’s standards cannot be treated as universal rules for all patients.

Some losses are also hard for a settlement to cover fully. A patient may have undergone treatment that ultimately failed to demonstrate benefit. The energy, hope, and time invested may resist the item-by-item accounting possible with a bill. This does not make those losses unimportant. It reminds us that society’s losses and the scope of payment ultimately available through a particular process may differ.

Patient protection therefore requires checking both whether legal avenues exist and whether people can actually enter them, whether information is clear enough, whether medical records have been retained, and whether relief is delivered. Keeping an avenue open still leaves much work before patients receive real help.

What kind of follow-up takes patients seriously?

The five preceding cases cannot be compressed into one kind of failure. Genuine uncertainty requires research. Breaches of data integrity require investigation. Specific injuries require clarification. Patients’ transitions require arrangements. Distinguishing these tasks helps each question receive its own answer.

In my judgment, assessing the handling of a drug controversy requires at least two sets of outcomes. The first is whether medicine and regulation corrected their judgment of future use in time. The second is whether people already bearing the consequences received sufficient information, continuity of clinical care, and relief appropriate to the facts.

A failed study should not automatically be judged unlawful. Serious breaches of integrity also cannot be set aside because a treatment may still have some use. Decisions about a drug’s future and responsibility for conduct can be discussed together. Existing patients’ wish to continue does not mean every future patient should start treatment.

This series began by asking why an already approved drug can still be withdrawn. It ends by returning to patients. The ability to correct mistaken or outdated decisions is essential to medicine. Ensuring that patients are not forgotten after that correction is an equally necessary part of what that ability should achieve.

A withdrawal announcement can end a supply. A settlement can end a case. Whether patients’ losses have been established and whether someone continues to address them still requires concrete follow-up.

Main sources

[1] U.S. District Court for the Eastern District of Louisiana: Vioxx product-liability litigation records; Merck, November 9, 2007: Original announcement of the $4.85 billion settlement program.

[2] Merck, second-quarter 2010 report: Vioxx claims-resolution and payment records. Used to confirm actual payments; the program’s total cannot be equated with the amount received by each patient.

[3] Merck, notes to the third-quarter 2016 report: Securities-settlement amount, court approval, and funding records. The $830 million was a securities-claims fund, with separate arrangements for legal fees and other matters. It cannot be included in a patient-injury fund.

[4] U.S. Department of Justice: 2011 announcement of the criminal and civil resolution and 2012 sentencing announcement.

[5] Court-authorized ChemoCentryx securities-case FAQ, hearing-date update, and revised settlement agreement dated May 15, 2026. The scope of the release and the non-admission clause appear in paragraph 1(pp) and paragraph 38, respectively.

[6] FDA: proposed withdrawal of Tavneos approval; MHRA: UK patient-transition arrangements.

[7] Vasculitis International: position that patients should not pay for failures in science; Lamb law firm’s investigation statement and Cory Watson’s case-solicitation page. The law-firm pages establish only investigation and solicitation, not filed proceedings, compensation awards, or payments.

[8] Amylyx, 2024 annual report: free-program time limits and disclosures of product revenue, returns, and rebates.

[9] Pfizer, June 21, 2010: Mylotarg withdrawal and arrangements for existing patients and IND use.

[10] FDA: decision withdrawing Avastin’s breast-cancer indication and explanation of off-label use of approved drugs.

[11] Dusetzina et al., JOP, 2015: original study of bevacizumab use and payer changes after regulatory decisions. This analyzes historical data from 2007–2012 and is not a promise of reimbursement for an individual in 2026.

[12] Amylyx, second-quarter 2026 report: Shih securities-case settlement arrangements and nature of the litigation; Pomerantz, the plaintiffs’ representative law firm: court-authorized proposed-settlement notice. Used to check the amount and the parties concerned, without treating an originally scheduled hearing date as the date of final payment.

Sources checked through October 28, 2026. This article focuses on public U.S. proceedings, using UK arrangements to compare patient transitions. Rights and responsibilities in different countries and individual cases require separate assessment. The article discusses medicine, science, and public issues; it does not constitute individual medical or legal advice. For patient-compensation programs not located, it reports only the results of this search of public sources.

Beyond the conclusion, there are still questions worth asking.

Medicine · Science · Ideas and reading

Follow Before the Conclusion as we stay curious and think independently together.

Text and image use

The original text was written by Before the Conclusion. You are welcome to share this article’s web link. Unless separately authorized, please do not republish or excerpt the text by copying, reposting, or distributing screenshots. Unless otherwise credited, article illustrations also may not be separately republished, copied, modified, or used commercially. Rights in cited materials belong to their respective rights holders.